# OPINION: Nipah is back in Kerala — and this time, the world has no vaccine and no plan

> In June 2026, health authorities in Kerala, southern India, confirmed the sixth outbreak of Nipah virus in the state since 2018. One confirmed case. 104 contacts under active monitoring. Intensive care units on alert. The same protocol, the same anxiety, the same uncomfortable question that surfaces every time this virus reappears: how long before our luck runs out? Nipah kills

- Author: Maxime Marquette
- Publisher: MadMax (https://mad-max.co)
- Section: Note
- Published: 2026-06-27
- Canonical URL: https://mad-max.co/en/article/billet-nipah-au-kerala-quand-un-seul-cas-suffit-a-terrifier-la-planete

## Key takeaways

- In June 2026, Kerala confirmed one case and placed 104 contacts under active monitoring, the sixth Nipah outbreak in the state since 2018.
- Nipah kills 40 to 75 percent of those infected, has no approved vaccine or proven antiviral, and is a WHO priority pathogen.
- Fruit bats of the genus Pteropus are the natural reservoir, and deforestation and habitat encroachment increase spillover risk.
- CEPI's funding is judged inadequate, the Pandemic Fund holds about $2 billion against an estimated $10 billion annual gap, and the Pandemic Treaty remains stalled.
- The author calls for public funding of vaccine trials, an advance market commitment, One Health surveillance, and formal recognition of Kerala's response capacity.

## Introduction: A virus the world keeps forgetting — until it can't

### The sixth resurgence since 2018

In **June 2026**, health authorities in **Kerala**, southern **India**, confirmed the sixth outbreak of **Nipah virus** in the state since **2018**. One confirmed case. **104 contacts** under active monitoring. Intensive care units on alert. The same protocol, the same anxiety, the same uncomfortable question that surfaces every time this virus reappears: how long before our luck runs out? **Nipah** kills between **40 and 75 percent** of those it infects depending on the strain. There is no approved vaccine. There is no proven antiviral treatment. What exists is an isolation protocol and the hope that the chains of transmission will be broken before they become a catastrophe.

The **World Health Organization** has classified **Nipah** as a priority pathogen — meaning it is on the short list of viruses most likely to trigger a global pandemic. Not because it spreads easily — it does not, at least not in its current form — but because its combination of high lethality, zoonotic origin, and the absence of medical countermeasures makes it uniquely dangerous if it were ever to acquire more efficient human-to-human transmission. Every outbreak in **Kerala** is, in the epidemiological vocabulary, a near miss. And near misses, by definition, do not always end well.

### Kerala's paradox: model of response, prisoner of recurrence

**Kerala** is not a failing state when it comes to health. Quite the opposite. Its public health infrastructure is among the most robust in **India** — high literacy rates, a dense network of hospitals, and a health bureaucracy that has learned, from bitter experience, to respond quickly to **Nipah** outbreaks. The **2018** outbreak — the first in the state — killed **17 of 19** confirmed cases, including a nurse who died caring for her patients. It was traumatic. It left a mark. And it produced a response protocol that is today considered a model by the **WHO** and international health organizations.

But here is the paradox: **Kerala's** model response capacity is not a solution to the underlying problem. It is an adaptive response to a structural failure. The structural failure is this: eight years after the first **Kerala** outbreak, after six resurgences, after dozens of studies identifying fruit bats of the genus **Pteropus** as the primary reservoir, the world still has no vaccine, no approved treatment, and no systematic strategy for reducing human exposure to the reservoir. **Kerala** is excellent at managing crises. The international community is failing at preventing them.

*Each time **Nipah** reappears in **Kerala**, I feel the same thing: a mixture of relief that the protocols are holding and a deep unease at the complacency that follows. We congratulate ourselves on having contained the outbreak — and then we go back to doing exactly what produced it. The fruit bats are still there. The human encroachment on their habitat is still accelerating. The vaccine is still not funded. And we wait for the next time, reassured by the last time, forgetting that statistical luck is not a health policy.*

## The Nipah virus: what it is, how it kills, why it terrifies

### A paramyxovirus with devastating clinical features

**Nipah virus** is a **paramyxovirus** of the genus **Henipavirus**, first identified in **1999** in **Malaysia** following an outbreak among pig farmers that killed **105 people** and led to the culling of over a million pigs. Its clinical picture is particularly severe: the infection begins with flu-like symptoms — fever, headache, muscle pain — before potentially progressing to **acute encephalitis**, causing convulsions, altered consciousness and, in the most severe cases, coma and death within **24 to 48 hours**. The case fatality rate varies between **40 and 75 percent**, depending on the strain and the quality of care available.

What makes **Nipah** particularly worrying from a pandemic risk perspective is its genetic plasticity. **RNA viruses** mutate rapidly, and several studies have identified specific mutations that could theoretically increase the efficiency of human-to-human transmission. Currently, transmission requires close contact with an infected person's bodily fluids — which limits natural spread but makes healthcare workers particularly vulnerable. The **2018 Kerala** outbreak killed the nurse **Lini Puthussery**, who had cared for infected patients without knowing the nature of the disease. Her death became a symbol of the medical community's exposure to a poorly understood threat.

### The fruit bat reservoir and deforestation dynamics

Fruit bats of the genus **Pteropus** — commonly known as flying foxes — are the natural reservoir of **Nipah virus**. They carry the virus without showing symptoms, excreting it through their urine, saliva, and the partially consumed fruits they drop. Human contamination occurs through consumption of these contaminated fruits — particularly date palm sap, harvested in **Bangladesh** and **West Bengal** through processes that expose it to bat excretions — or through direct contact with infected animals or their secretions.

The accelerating deforestation of bat habitats in **South Asia** is pushing these animals closer to human settlements and agricultural areas, multiplying the opportunities for spillover. This dynamic is not specific to **Nipah** — it is the common thread linking the emergence of most zoonotic diseases of the last thirty years: **SARS**, **MERS**, **Ebola**, **COVID-19**. The destruction of natural habitats creates the conditions for viral traffic between animal populations and humans. Every deforested hectare in **Kerala**, in **Bangladesh**, in **Indonesia** is a potential bridge between animal viruses and human populations. We are building these bridges ourselves, methodically, at an accelerating pace.

*There is something profoundly disturbing about knowing the source of the problem, having the data to confirm it, having the tools to address it — and doing nothing systemic. The link between deforestation, bat habitat loss, and **Nipah** spillovers is not a hypothesis. It is documented. Yet the conversation after each outbreak focuses on isolation protocols and contact tracing, never on the structural causes. It is like mopping the floor while leaving the tap running. Efficient mopping. Catastrophic water management.*

## The 2026 outbreak: facts, response, and the 104 under surveillance

### The confirmed case and initial response

The **2026** outbreak began with a single confirmed case — a patient in **Kerala** who tested positive for **Nipah virus** in **June 2026**. The Kerala health authorities, drawing on the protocols developed since **2018**, immediately activated their emergency response plan: identification and isolation of all close contacts, enhanced surveillance in health facilities, public information dissemination, and direct communication with the **WHO**. The **104 contacts** placed under active monitoring represent the known risk perimeter — people who had direct or indirect contact with the confirmed patient before isolation.

The quality of this initial response deserves to be acknowledged. In many parts of the world, a single **Nipah** case would generate significant delays in identification, notification, and contact tracing. **Kerala** has built a system that minimizes these delays. The **WHO** was notified rapidly. International protocols were activated. This speed is not automatic — it is the product of years of institutional learning, investment in public health infrastructure, and a culture of transparency that is not universal among regional health authorities. The **2026** response, in its early stages, is textbook. The question is whether it will be enough.

### The 104 contacts: a map of risk

The **104 contacts** under active monitoring are not all equal in terms of risk. Epidemiologists distinguish between **high-risk contacts** — people who had direct exposure to bodily fluids of the confirmed case — and **low-risk contacts** — people who were in the same environment but had no direct exposure. The distribution of these **104** people across the two categories will determine the true scale of the threat. If the majority are low-risk, the situation is manageable. If a significant proportion are high-risk, the probability of secondary cases increases substantially.

The **21-day** incubation period of **Nipah** means that this active monitoring phase is not a formality. Every person under surveillance must be followed daily, their temperature monitored, their symptoms reported immediately. This requires significant human and logistical resources — resources that **Kerala** has, but that many of the regions where **Nipah** could next emerge do not. The **2026** outbreak is, for the moment, a test of a known system. The next outbreak, elsewhere, could be a test of systems that do not yet exist.

*I think about those **104** people every time I read this type of alert. They are waiting. They check their temperature twice a day. They wonder whether what they feel is anxiety or the beginning of something worse. And they wait — twenty-one days — hoping that the answer will be nothing. That kind of waiting is its own form of suffering. And it is a suffering that our failure to invest in a vaccine condemns them to, repeatedly.*

## The absence of a vaccine: a conscious collective choice

### CEPI and the chronic underfunding of neglected pathogens

The **Coalition for Epidemic Preparedness Innovations** (**CEPI**) was created in **2017** — after the **West African Ebola crisis** — with precisely the mission of funding the development of vaccines against priority pathogens, including **Nipah**. Several vaccine candidates are in various stages of development. A **Nipah vaccine** based on the **Hendra virus** envelope glycoprotein — developed by **Vaccitech** and others — has shown promising results in Phase I trials. But promising Phase I results and a licensed, deployable vaccine are separated by a chasm of funding, clinical trials, and regulatory processes that takes years and costs hundreds of millions of dollars.

**Nipah** suffers from the classic paradox of neglected diseases: it is too rare, in its current form, to attract the pharmaceutical investment that a market logic would justify, but potentially catastrophic enough to warrant a public investment that governments consistently fail to provide. **CEPI** has attempted to bridge this gap, but its resources — a few hundred million dollars across all its programs — are inadequate relative to the breadth of threats it is supposed to address. After six outbreaks in eight years in a single Indian state, the absence of an approved vaccine is not a scientific failure. It is a political choice — a revealed preference for reactive management over proactive prevention.

### The COVID-19 lesson not fully learned

The **COVID-19 pandemic** demonstrated — in the most painful possible way — that investing in pandemic preparedness before a crisis is vastly more cost-effective than responding to one after it hits. The economic and human cost of **COVID-19** dwarfs by orders of magnitude what would have been required to build robust global preparedness infrastructure, including vaccine platforms for priority pathogens. This lesson was loudly proclaimed in the months following the **2020** shock. The **Pandemic Fund** was created under the **G20**. Commitments were made. Declarations were signed.

By **2026**, many of these commitments have not been followed through with the sustained funding and political attention they required. The urgency of **COVID-19** created a temporary window of political will for pandemic preparedness — a window that has largely closed as the acute memory of the pandemic fades and other crises compete for attention. **Nipah** is still without an approved vaccine. The **Pandemic Treaty** negotiations at the **WHO** have been slow and contentious. And in **Kerala**, health workers are once again isolating contacts, taking temperatures, and hoping the chain breaks before it doesn't.

*After **COVID-19**, I genuinely believed we had crossed a threshold of collective awareness about pandemic risk. I was wrong. The political will that a catastrophe generates evaporates faster than the memory of the catastrophe itself. We went from "never again" to "we'll cross that bridge when we come to it" in about eighteen months. The **Nipah** vaccine is still not funded. The **Pandemic Treaty** is still stalled. And somewhere in **Kerala**, health workers are doing, for the sixth time, what a vaccine would have made unnecessary.*

## The WHO alert and international coordination

### Disease Outbreak News and global notification mechanisms

The **WHO** publishes **Disease Outbreak News** (**DON**) for events meeting established notification thresholds under the **International Health Regulations** (**IHR 2005**). The **2026 Kerala Nipah** outbreak triggered such a notification, making it part of the global health surveillance record. This mechanism — often invisible to the general public — is in fact a critical piece of global health architecture: it ensures that health authorities worldwide are informed of priority events, can calibrate their own surveillance accordingly, and can coordinate support if needed.

The **WHO** notification system is, in theory, the foundation of global health solidarity. In practice, its effectiveness depends on member states' willingness to notify rapidly and transparently — a willingness that is not always present when political and economic costs of disclosure are perceived as high. **India**'s notifications on **Nipah** have generally been prompt and transparent, which partially explains why **Kerala's** response is regarded as a model. Transparency enables coordination. Coordination enables containment. The incentive structure of the **IHR** should reward this transparency more explicitly than it currently does.

### Regional preparedness and the South Asian Nipah corridor

The **Nipah** threat is not limited to **Kerala**. **Bangladesh** has experienced repeated outbreaks since **2001**, with a distinct transmission pattern — primarily through consumption of raw date palm sap contaminated with bat secretions. **West Bengal**, sharing borders with **Bangladesh** and neighboring **Kerala**, has seen cases. The epidemiological geography of **Nipah** defines a **South Asian corridor** of risk that spans multiple countries, languages, health systems, and political jurisdictions.

Coordinated regional preparedness — shared surveillance systems, joint outbreak response protocols, harmonized case definitions, coordinated stockpiling of personal protective equipment and diagnostics — is essential for managing a pathogen that does not respect national boundaries. The **South-East Asia Regional Office** of the **WHO** (**SEARO**) has made progress on regional coordination, but resources and political commitment vary considerably across member states. Building a regional **Nipah** response architecture that is robust enough to handle a larger outbreak — one that crosses state or national borders simultaneously — remains an unfinished priority.

***Nipah** does not care about borders. It does not read **WHO** frameworks or bilateral health agreements. It follows animal migration patterns, human food habits, and the slow logic of habitat destruction. Building a response architecture that matches the geography of the threat — rather than the geography of political jurisdictions — is the intellectual challenge at the heart of pandemic preparedness. We are better at it than we were in **2018**. We are not yet good enough.*

## The healthcare workers in the line of fire

### The martyrdom of Lini Puthussery and its lasting lessons

The name **Lini Puthussery** should be known beyond **Kerala**. She was the nurse who died in **2018** after caring for a **Nipah**-infected patient without knowing the diagnosis, without adequate protection, and without any treatment to offer her patients or herself. Her death — and the deaths of others in that first outbreak — triggered the institutional response that made **Kerala's** subsequent outbreak management so much more effective. She paid, with her life, for lessons that should have been learned before she ever had to face that virus.

By **2026**, **Kerala's** healthcare workers have personal protective equipment protocols, training, and institutional memory that **Lini** did not have. But the underlying vulnerability remains: they are treating a disease for which there is no treatment, using protective measures that reduce but do not eliminate risk, in facilities that can be overwhelmed if transmission accelerates. The **2026** response is better than **2018**. It should not have taken a martyr to make it so — and the fact that an approved vaccine still does not exist means that healthcare workers in **2026** remain exposed to a risk that international investment could have substantially reduced.

### Mental health costs and the recurring burden on health systems

Each **Nipah** outbreak in **Kerala** imposes costs that go beyond the direct clinical management of cases. The mental health burden on healthcare workers — anxiety, vigilance fatigue, the psychological weight of managing a deadly disease with limited tools — is significant and cumulative. Health workers who have lived through three, four, five outbreaks carry a form of chronic stress that standard occupational health systems are not well equipped to address. Research on the psychological impacts on health workers in **Kerala's** repeated **Nipah** outbreaks is limited — itself a gap in global understanding of the full costs of recurring outbreak management.

The economic costs extend to the broader **Kerala** economy. Tourism, agricultural markets, and daily commerce are disrupted during outbreak periods as precautionary measures and public anxiety reduce movement. The **2018** outbreak is estimated to have cost the state hundreds of millions of rupees in economic activity forgone. Each subsequent outbreak repeats this disruption at some scale. The aggregate economic cost of the absence of a vaccine — across all six outbreaks since **2018** — is a number that should be calculated explicitly and placed on the table in international discussions about pandemic preparedness funding. It would make a compelling case for investment.

*We count the dead. We count the confirmed cases. We rarely count the exhausted nurses, the frightened contact-tracers, the tourism operators whose seasons collapse every time **Nipah** returns. The full cost of our preparedness failure is not only measured in fatalities — it is measured in the cumulative depletion of the human and economic resources of the communities that absorb, again and again, the consequences of a vaccine we chose not to fund.*

## The politics of pandemic preparedness: where funding goes and why

### The hierarchy of pharmaceutical investment

The global pharmaceutical industry invests in vaccine development according to a logic that is primarily commercial. **Diseases with large, wealthy markets** attract investment. Diseases that primarily affect populations in low- and middle-income countries, that produce outbreak clusters rather than continuous mass demand, and that require ultra-cold chain or complex deployment logistics — these diseases attract much less private investment. **Nipah** checks all the boxes for pharmaceutical neglect: it is currently concentrated in **South Asia**, it is episodic rather than continuous, and its outbreak scale — a few dozen to a few hundred cases — does not produce the mass demand that justifies commercial vaccine development.

This market logic is not a moral condemnation of the pharmaceutical industry — it is a description of how market incentives work, and why market incentives alone are insufficient for pandemic preparedness. The argument for public investment in vaccines against pathogens like **Nipah**, **Marburg**, and **Crimean-Congo hemorrhagic fever** is not philanthropic. It is strategic: the cost of developing these vaccines in advance is a fraction of the cost of the global disruption they could cause if they were to acquire pandemic potential before countermeasures are ready. This is basic risk management mathematics. It is also, apparently, insufficiently compelling to produce the sustained political commitment required.

### The international governance gap in pandemic preparedness funding

The **Pandemic Fund**, established under the **G20 Indonesia Presidency** in **2022**, was created specifically to address the global health security financing gap. By **2026**, its resources — approximately **$2 billion** in initial pledges — are widely considered insufficient relative to the scale of the preparedness challenge. The **WHO** estimates that the annual global investment gap in pandemic preparedness is on the order of **$10 billion per year**. The **Pandemic Fund** addresses a fraction of this gap, and its governance — with competing national interests represented on its board — has made prioritization contentious.

The broader **Pandemic Treaty** negotiations, ongoing since **2022**, were intended to create a binding international framework for pandemic preparedness and response, including equitable access to vaccines and medical countermeasures. By mid-**2026**, negotiations remain difficult, with persistent disagreements between high-income and low-income countries over intellectual property rules, benefit-sharing, and the balance between national sovereignty and global obligations. The sixth **Nipah** outbreak in **Kerala** occurs in the middle of a world still debating the governance framework that should have been in place years ago.

*The **Pandemic Treaty** negotiations have been described as a diplomatic achievement every time they produce a new draft, and as a crisis every time negotiations stall. What they have not produced — yet — is a binding, funded, enforceable framework for pandemic preparedness that treats the threat of pathogens like **Nipah** with the seriousness it deserves. The distance between the urgency of the problem and the speed of the political response is, frankly, frightening. But it is not surprising. It is, depressingly, normal.*

## The global risk calculus: from outbreak to pandemic potential

### What would it take for Nipah to become a pandemic threat?

**Nipah** in its current form is not a pandemic pathogen. Its basic reproduction number (**R0**) is estimated to be below 1 in most outbreaks — meaning that, on average, each infected person transmits to fewer than one other person. Chains of transmission tend to be short and self-limiting when contact and isolation protocols are implemented promptly. This is why six outbreaks in **Kerala** have not produced a pandemic — the epidemiology, in its current form, works against wide propagation.

But the concern — and the reason **Nipah** sits on the **WHO** priority list — is the possibility of adaptive evolution. Specific mutations in the attachment glycoprotein or the fusion protein of **Nipah** could theoretically increase airborne transmission efficiency without necessarily reducing virulence. This is not an inevitable trajectory — most viruses do not acquire pandemic potential through mutation. But with a case fatality rate between **40 and 75 percent**, even a modest increase in transmissibility would produce consequences that are difficult to overstate. A **Nipah** strain with **COVID-19** transmission dynamics and **Nipah's** current lethality would be among the most catastrophic pathogens in modern history.

### The surveillance imperative: seeing threats before they become crises

Detecting the evolution of **Nipah** toward enhanced transmissibility — if it were to occur — requires a global genomic surveillance system of a quality that does not yet uniformly exist. **COVID-19** produced a major investment in genomic surveillance capabilities, particularly in high-income countries. But the regions where **Nipah** circulates — **South Asia**, parts of **Southeast Asia** — are precisely the regions where genomic surveillance capacity remains uneven. Detecting a dangerous mutation early requires sequencing capacity, bioinformatics expertise, and international data-sharing protocols that are still being built.

The **Global Initiative on Sharing All Influenza Data** (**GISAID**), extended beyond influenza during **COVID-19**, provides a partial framework for sharing pathogen genomic data. But systematic **Nipah** surveillance — continuous, not just outbreak-triggered — requires sustained investment in bat population monitoring, environmental sampling, and human-animal interface surveillance that goes beyond what current programs provide. The science of anticipatory surveillance is advancing. Its deployment, at the scale and in the locations where it is most needed, lags behind.

*I am not an epidemiologist. But I can read risk tables. And the table that shows **Nipah's** current R0 below 1 alongside its lethality of up to **75 percent** tells a clear story: we are currently fortunate, not safe. The distance between **Nipah** as it exists today and **Nipah** as it could exist after the right combination of mutations is smaller than the distance between our current preparedness and what that scenario would require. That gap is the true measure of our collective vulnerability.*

## India's response and the lessons for global health architecture

### A federal health system under pressure

**India's** constitutional structure places public health primarily under state jurisdiction — meaning that **Kerala's** exceptional outbreak management capacity is not automatically replicated in other Indian states. A **Nipah** outbreak in **Uttar Pradesh** or **Bihar** — with less robust public health infrastructure — would present a significantly different challenge. The country's **National Centre for Disease Control** (**NCDC**) and the **Indian Council of Medical Research** (**ICMR**) provide central coordination, but the operational response remains primarily at the state level. This creates a preparedness landscape that is uneven within a single large country.

**India's** role in global pandemic preparedness is growing — it is the world's largest producer of vaccines, hosting manufacturers that supplied the majority of **COVID-19** vaccines deployed in low- and middle-income countries. This manufacturing capacity is a genuine global asset. But the translation of manufacturing capacity into proactive vaccine development for priority pathogens requires investment signals — purchase commitments, guaranteed markets, advance market commitments — that the international community has been slow to establish for pathogens like **Nipah**. The capacity to respond is present. The incentives to develop the tools in advance are not.

### The international community's debt to Kerala

**Kerala** has, over eight years and six outbreaks, absorbed the consequences of a global preparedness failure that is not of its making. It has developed response protocols, trained healthcare workers, built institutional memory, and contained outbreak after outbreak — at cost to its health system, its economy, and the wellbeing of its population. The international community has benefited from this containment without adequately compensating for it, either in the form of sustained research investment or in the form of funding for the vaccine development that would reduce the burden **Kerala** bears.

There is something deeply inequitable about this arrangement. The populations most exposed to **Nipah** — in **Kerala**, in **Bangladesh**, in **West Bengal** — are not the populations making the funding decisions that determine whether a vaccine gets developed. They bear the risk. Others hold the budgets. The **WHO's** priority pathogen list is, among other things, a moral claim on international resources. Translating that moral claim into actual funding for **Nipah** vaccine development is a matter of political will. That political will has been declared many times. It has not yet been fully exercised.

*I want to be precise here: **Kerala's** response to **Nipah** is admirable. The healthcare workers, epidemiologists, and public health officials who have managed these six outbreaks have done extraordinary work under extraordinary pressure. But admiring a state for managing a crisis that should not have been allowed to recur six times is a strange form of praise. The highest form of respect for **Kerala's** response capacity would be to render it unnecessary — by funding the vaccine.*

## What must change: a concrete agenda for action

### Accelerate Nipah vaccine development with public funding

The most urgent priority is straightforward: adequately fund the most advanced **Nipah vaccine** candidates through Phase II and Phase III clinical trials. Several candidates exist with promising Phase I data. The bottleneck is not scientific — it is financial. The cost of completing **Nipah** vaccine development is estimated in the hundreds of millions of dollars — a fraction of the economic damage produced by a single major outbreak, and a vanishingly small fraction of the cost of a **Nipah** pandemic. The **CEPI** framework is the right vehicle. It needs the funding to match its mandate. **G7** and **G20** governments should make **Nipah** vaccine completion a named priority in their pandemic preparedness commitments.

In parallel, an advance market commitment for a licensed **Nipah vaccine** — guaranteeing a minimum purchase price for a defined number of doses — would provide the commercial signal needed to attract pharmaceutical co-investment. The model was used for **COVID-19** vaccines with considerable success. Applied to **Nipah**, it would dramatically accelerate the timeline to availability. This is not a utopian proposal. It is a policy tool with proven effectiveness, awaiting political decision.

### Build systematic human-animal interface surveillance

A **Nipah** vaccine is a critical tool, but it is not the only lever. Systematic reduction of human exposure to the virus reservoir — through habitat protection, agricultural practice changes, and targeted public health communication in high-risk communities — can reduce spillover events. This requires sustained monitoring of bat populations in the **Nipah** corridor, including genomic surveillance to detect potential mutations toward enhanced transmissibility. It requires community engagement programs in the regions where human-bat contact is most frequent — particularly around the harvesting of date palm sap in **Bangladesh** and similar practices elsewhere.

The **One Health** approach — integrating human, animal, and environmental health surveillance — is the conceptual framework for this work. Its translation into funded, operational programs at the country level is uneven. Strengthening **One Health** surveillance in the **Nipah** corridor is a long-term investment that would reduce not only **Nipah** risk but also the risk of other zoonotic spillovers from the same reservoir. This is pandemic preparedness at its most efficient — addressing root causes rather than managing downstream consequences.

*The **One Health** framework has been the consensus position of international health organizations for over a decade. What it has not been, consistently, is adequately funded. I am tired of frameworks that everyone endorses and no one resources sufficiently. The **Nipah** problem has a conceptual solution — it is written in dozens of **WHO** reports and academic papers. What it lacks is the money and the political will to implement it. Those two things are not technical problems. They are choices.*

## The media's role in outbreak management: between transparency and panic

### How information quality shapes public response

The quality of public communication during a **Nipah** outbreak matters — both for effective containment and for avoiding the panic that can undermine response efforts. Premature or inaccurate reporting of **Nipah** cases has, in past outbreaks, led to flight from affected areas, overwhelming of health facilities by worried-well patients, and stigmatization of affected communities — all of which complicate containment. **Kerala's** health authorities have developed increasingly sophisticated public communication strategies over the course of six outbreaks: clear, factual messaging about transmission risk, regular updates on the status of contact monitoring, and consistent emphasis on the manageable nature of the current outbreak while acknowledging its seriousness.

The media ecosystem in which this communication occurs has changed dramatically since **2018**. Social media amplification of fear — based on misunderstood statistics, historical comparisons to larger outbreaks, or deliberately sensationalized content — can generate panic that is disproportionate to the actual epidemiological situation. The **2026** outbreak has already produced a cycle of social media anxiety that has required active management by health authorities. This is now a structural feature of outbreak response — not a side issue, but a core communication challenge that requires resources, strategy, and speed that public health systems were not originally designed to provide.

### International media attention and its perverse incentives

International media attention to **Nipah** outbreaks tends to be inversely proportional to the response quality. Precisely because **Kerala's** response is effective — the outbreak is identified quickly, contacts are traced promptly, the chain breaks before major secondary transmission — the story generates brief attention and then disappears. A poorly managed outbreak that spreads further would generate sustained coverage. This creates a perverse incentive structure in which success in containment generates less attention — and therefore less political pressure for the long-term investments that would make containment unnecessary.

This is not a media criticism — it is a structural feature of how news cycles work. It is also an argument for the kind of sustained expert advocacy and institutional pressure that can maintain political attention to pandemic preparedness between crises. **CEPI**, the **WHO**, and civil society organizations working on global health security perform this function, but their voice is often drowned out when no major outbreak is generating headlines. The sixth **Nipah** outbreak in **Kerala** is an opportunity to make that case again — and to insist that success at containment is not a reason for complacency, but a reason to act before the seventh.

*Success stories in public health are among the most difficult things to communicate. A disease that did not spread because protocols worked is not a story — it is the absence of a story. This invisibility of prevention is one of the deepest structural problems in global health advocacy. The lives saved by a vaccine that was never created cannot be counted. The outbreaks averted by surveillance systems that caught a spillover early are not in the headlines. We count catastrophes. We rarely count the catastrophes that did not happen because someone invested correctly, in advance. We should learn to count those too.*

## The geopolitics of health: when pandemic risk meets strategic competition

### Health security as a dimension of national power

The management of pandemic risk has become, since **COVID-19**, an explicit dimension of national security and geopolitical competition. Countries' ability to develop, produce, and deploy vaccines against emerging pathogens is now understood as a strategic capability — not just a public health capacity. This framing has generated new investment in domestic vaccine manufacturing in **Europe**, **the United States**, and major emerging economies. It has also complicated international cooperation: when pandemic preparedness is framed primarily as national security, the incentive to share data, tools, and resources with other countries is reduced.

For pathogens like **Nipah** — concentrated in **South Asia**, currently manageable at the local level, not yet a threat to high-income countries — this framing of health as national security is a double-edged sword. It has increased awareness of pandemic risk and generated some additional investment. But it has also produced a kind of preparedness nationalism that prioritizes domestic stockpiling over the global coordination that actually prevents pandemics from developing. A **Nipah** outbreak contained in **Kerala** is a global public good. It should be funded as one.

### The equity imperative in pandemic preparedness

The distribution of pandemic preparedness investment and capacity across the globe is deeply inequitable. High-income countries — which will be most protected from the immediate consequences of a **Nipah** outbreak, given its current geographic concentration — hold the majority of global health security resources. The communities most at risk — in **Kerala**, **Bangladesh**, **West Bengal** — have built impressive response capacity under resource constraints, but they should not bear this burden alone. The equitable dimension of pandemic preparedness is not charity — it is rational risk management. A pathogen contained in a low-income setting is a pathogen that does not reach a high-income setting. The investment in global health security is an investment in domestic security, understood correctly.

The principle of **international solidarity in health** — enshrined in the **WHO Constitution** and reiterated in every major global health governance framework — needs to move from declaration to practice. For **Nipah**, this means: funded vaccine development through CEPI, advance purchase commitments that create production incentives, sustained support for regional surveillance capacity in **South Asia**, and a pandemic preparedness framework that explicitly recognizes the contribution of outbreak-bearing communities to global health security. **Kerala** is protecting the world. The world should help pay for it.

*The rhetoric of global health equity is one of the most consistently repeated and least consistently practiced principles in international health governance. Every major report says the same thing: the investments in low- and middle-income country health systems are insufficient, the burdens are unequally distributed, the current arrangement is not sustainable. Every major report has said this for twenty years. And the arrangement continues. I am not cynical enough to think it will never change. But I am tired of declarations that are not followed by budgets.*

## The 2026 outbreak in context: a symptom of a larger failure

### Six outbreaks, one structural failure

The sixth **Nipah** outbreak in **Kerala** since **2018** is not, primarily, a story about a virus. It is a story about a system — a global health preparedness system that has recognized a clear and present danger, has the scientific tools to address it, and has consistently failed to mobilize the political and financial will to do so. The virus has not changed fundamentally. The bats have not gone away. The habitat destruction continues. And the international community is still having the same conversations about pandemic preparedness funding that it was having in **2018**, in **2020**, in **2022**. The sixth outbreak is a symptom of a structural failure. The seventh — if it comes — will be too.

This is not a counsel of despair. It is a call for precision in diagnosis. The problem is not that we do not understand **Nipah**. It is not that we lack response protocols. It is not that **Kerala's** health workers are insufficiently dedicated. The problem is that the international funding and governance architecture for pandemic preparedness consistently underinvests in vaccines and surveillance for pathogens that have not yet become global emergencies. Changing this requires political will at the highest levels — the kind of will that **COVID-19** temporarily generated and that has since partially dissipated. Rebuilding it is urgent. The clock is running.

### The world is one mutation away from a different conversation

The epidemiological community has a phrase for situations like the current **Nipah** moment: a **slow emergency**. The threat is real, documented, quantifiable. The consequences of inaction are foreseeable. But the timeline is uncertain enough to allow delay — each contained outbreak reducing the urgency slightly, each quiet year without a major event feeding the temptation to treat preparedness as a lower priority. The **Nipah** situation in **2026** is a slow emergency. The conversation would change immediately if the current outbreak were to produce a chain of secondary transmissions, or if genomic sequencing of the circulating virus were to reveal a mutation toward enhanced airborne spread.

We should not wait for that conversation. We should have it now — on the basis of the risk data we already have, the preparedness gaps we already know, and the tools we could already be developing. A **Nipah vaccine** that is licensed and stockpiled before the seventh **Kerala** outbreak — or before the first outbreak somewhere with less robust response capacity — is worth more than a hundred emergency responses after the fact. This is not speculation. This is arithmetic. The world can afford the investment. What it appears to lack is the political will to make it.

*I am writing this during the sixth outbreak. I hope, genuinely, that the contacts are all cleared, that no secondary cases emerge, and that this text reads, in a few weeks, as an alarm that turned out to be unnecessary. I hope for that. But I am also aware that hope is not a public health strategy. And that if this particular outbreak ends well, the real test will not have been the outbreak — it will be what the international community does in the weeks and months that follow, when the cameras are pointed elsewhere and the urgency has momentarily faded. That is when political will is most needed and most often absent.*

## The path forward: from managed crisis to genuine prevention

### Concrete steps that can be taken now

Moving from repeated crisis management to genuine prevention of **Nipah** outbreaks requires actions that are specific, funded, and accountable. First, the **G7** and **G20** should name **Nipah vaccine completion** as a priority in their annual health security commitments, with specific funding tranches to **CEPI** tied to clinical trial milestones. Second, an **advance market commitment** for a licensed **Nipah vaccine** should be structured and announced — providing the manufacturing investment signal before the vaccine is needed in a crisis. Third, **One Health** surveillance in the **South Asian Nipah corridor** should be supported with sustained international funding, including genomic sequencing capacity and cross-border data sharing protocols.

Fourth, the **Pandemic Treaty** should include specific provisions for vaccines against **WHO priority pathogens** — including guaranteed access arrangements that ensure vaccine availability in the regions of highest outbreak risk as a first priority, not as an afterthought. Fifth, **Kerala's** response capacity and accumulated outbreak experience should be formally recognized and supported as a global health asset — through sustained partnership with the **WHO SEARO**, funding for documentation and sharing of protocols, and inclusion of **Kerala's** health officials in global pandemic preparedness governance processes. These are not revolutionary proposals. They are the logical next steps from the evidence in front of us.

### The political economy of prevention

The fundamental obstacle to all of the above is political economy, not science. Prevention is invisible. A vaccine that stops an outbreak is a story that does not happen. A surveillance system that detects a mutation early is a threat that does not materialize. The political economy of democracies tends to reward visible action over invisible prevention — a ribbon-cutting for a new hospital generates political credit that a well-funded surveillance system does not. Overcoming this structural bias requires advocates — in civil society, in the scientific community, in the media — who are willing to make visible the costs of under-investment, the near-misses that statistics can capture, and the lives that prevention saves.

It also requires political leaders who are willing to spend political capital on long-term risk reduction rather than short-term crisis response. These leaders exist. They are often found in countries that have experienced the costs of pandemic failure — and **Kerala** has produced some of the most articulate advocates for global pandemic preparedness investment, partly because its population has lived with the consequences of inadequate global preparation for eight years. Their voice should be amplified. Their experience should inform global policy. And their repeated demonstration that effective response is possible — even without a vaccine — should be honored not with congratulations, but with the investment that makes their sacrifice unnecessary in the future.

*I have said it several times in this piece, and I will say it one more time because it deserves repetition: the absence of a **Nipah vaccine** in **2026**, after eight years of documented outbreaks in a single state, is a political failure. Not a scientific failure. Not a technical failure. A political failure. And naming it as such is the first step toward changing it. Because unlike viruses, political failures can be corrected — if enough people decide that the status quo is unacceptable. That decision starts with being willing to call things by their right name.*

## Conclusion: the seventh outbreak cannot find us this unprepared

### What six outbreaks should have taught us

The sixth **Nipah** outbreak in **Kerala** since **2018** has confirmed, once again, that the state's response capacity is exceptional. It has also confirmed, once again, that the international health community's preparedness for **Nipah** remains inadequate — no approved vaccine, incomplete surveillance architecture, insufficient pandemic treaty progress. If the current outbreak is contained, as previous ones have been, the correct response is not relief. It is determination — to use the window of relative calm to make the investments that will reduce the probability and severity of a seventh outbreak, or of a first outbreak somewhere with less robust response capacity.

The calculus is simple. The scientific pathway to a **Nipah vaccine** exists. The funding to travel that pathway is within the means of the international community. The political will is the limiting factor. Every outbreak that ends without a pandemic is borrowed time — time that should be used to close the gaps that the next outbreak could exploit. The world has been lucky with **Nipah** for eight years. Luck is not a strategy. The seventh outbreak deserves better than the same conversation we have had after each of the previous six. It deserves a vaccine.

### A final word on urgency and responsibility

Urgency without specificity is useless. The international health community is very good at declaring urgency and very poor at sustaining the specific commitments that urgency requires. The concrete agenda for **Nipah** preparedness is not mysterious — it has been written in **WHO** reports, **CEPI** strategy documents, and academic journals for years. What is needed is not more analysis. What is needed is the decision by the governments of high-income countries, backed by the allocation of real resources, to treat the prevention of the next **Nipah** outbreak as a priority that is maintained through the periods of calm between crises — not only rediscovered when the next case is confirmed in **Kerala**. The seventh outbreak is coming. The question is only whether we will be better prepared than we were for the sixth.

*I end this piece with a conviction that I hold as clearly as I hold any journalistic judgment: the sixth **Nipah** outbreak in **Kerala** will not be the last. The structural conditions that produce it — habitat destruction, absence of a vaccine, inadequate surveillance — have not changed. What can change is the international response to those structural conditions. Changing it requires people — journalists, scientists, advocates, citizens — who refuse to let the quiet periods become periods of forgetting. I am one of those people. And I am asking you, reading this, to be one too.*

**By Maxime Marquette, columnist**

## Columnist's transparency note

### Editorial stance

I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies.

I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events.

### Method and sources

This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here.

**Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies.

**Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations.

When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**.

### Nature of the analysis

The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted.

My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors.

This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text.

## Sources

### Primary sources

- [World Health Organization — Disease Outbreak News: Nipah virus — India (Kerala), June 2026](https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON609)

- CEPI — Nipah virus priority pathogen profile and vaccine development portfolio — 2026

- [Ministry of Health and Family Welfare, India — Nipah virus outbreak update, Kerala — June 2026](https://www.mohfw.gov.in/)

### Secondary sources

- [Euromaidan Press — Nipah in Kerala: a test of global pandemic preparedness — June 2026](https://euromaidanpress.com/2026/06/nipah-kerala-global-preparedness/)

- Foreign Policy — Nipah's sixth Kerala outbreak exposes chronic preparedness gaps — June 2026

- The Guardian — WHO alert as Nipah resurfaces in Kerala for sixth time since 2018 — June 2026

---

Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/billet-nipah-au-kerala-quand-un-seul-cas-suffit-a-terrifier-la-planete